<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Although a number of <z:chebi fb="1" ids="36044">antiviral drugs</z:chebi> inhibit replication of Epstein-Barr virus (EBV) in cell culture, and <z:chebi fb="4" ids="2453">acyclovir</z:chebi> (ACV) suppresses replication in vivo, currently available drugs have not proven effective for treatment of EBV-associated diseases other than <z:e sem="disease" ids="C0206186" disease_type="Neoplastic Process" abbrv="">oral hairy leukoplakia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="36622">Benzimidazole</z:chebi> riboside compounds represent a new class of antiviral compounds that are potent inhibitors of human cytomegalovirus (HCMV) replication but not of other herpesviruses </plain></SENT>
<SENT sid="2" pm="."><plain>Here we characterize the effects of two compounds in this class against lytic replication of EBV induced in a Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell line latently infected with EBV </plain></SENT>
<SENT sid="3" pm="."><plain>We analyzed linear forms of EBV genomes, indicative of lytic replication, and episomal forms present in latently infected cells by terminal probe analysis followed by Southern blot hybridization as well as the high-molecular-weight unprocessed <z:mp ids='MP_0001799'>viral</z:mp> DNA by pulsed-field gel electrophoresis </plain></SENT>
<SENT sid="4" pm="."><plain>D-<z:chebi fb="0" ids="26565">Ribofuranosyl</z:chebi> <z:chebi fb="0" ids="36622">benzimidazole</z:chebi> compounds that act as inhibitors of HCMV DNA maturation, including BDCRB (5, 6-dichloro-2-<z:chebi fb="1" ids="22927,47265">bromo</z:chebi>-1-beta-D-<z:chebi fb="0" ids="26565">ribofuranosyl</z:chebi>-1H-<z:chebi fb="0" ids="36622">benzimidazole</z:chebi>), did not affect the accumulation of high-molecular-weight or monomeric forms of EBV DNA in the induced cells </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast, the generation of linear EBV DNA as well as precursor <z:mp ids='MP_0001799'>viral</z:mp> DNA was sensitive to the L-riboside 1263W94 [5, 6-dichloro-2-(isopropylamino)-1-beta-L-<z:chebi fb="0" ids="26565">ribofuranosyl</z:chebi>-1H-<z:chebi fb="0" ids="36622">benzimidazole</z:chebi>] </plain></SENT>
<SENT sid="6" pm="."><plain>The 50% inhibitory concentration range for 1263W94 was 0.15 to 1 </plain></SENT>
<SENT sid="7" pm="."><plain>1 microM, compared with 10 microM for ACV </plain></SENT>
<SENT sid="8" pm="."><plain>Thus, 1263W94 is a potent inhibitor of EBV </plain></SENT>
<SENT sid="9" pm="."><plain>In addition, 1263W94 inhibited the phosphorylation and the accumulation of the essential EBV replicative cofactor, early antigen D </plain></SENT>
</text></document>